These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24224637)

  • 21. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
    Racsa PN; Whisman TR; Worley K
    Curr Med Res Opin; 2015; 31(10):1933-40. PubMed ID: 26368665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
    Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
    Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care costs among renal cancer patients using pazopanib and sunitinib.
    Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
    Schmidinger M; Wittes J
    Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
    Annala M; Nappi L; Azad AA; Mo F; Fazli L; Chi KN; Wyatt AW
    Clin Genitourin Cancer; 2017 Feb; 15(1):e145-e150. PubMed ID: 27324055
    [No Abstract]   [Full Text] [Related]  

  • 27. Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study.
    Bracarda S;
    Ann Oncol; 2015 Jul; 26(7):1512-3. PubMed ID: 25846555
    [No Abstract]   [Full Text] [Related]  

  • 28. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 29. Sunitinib 2 weeks on, 1 off: strengths and weaknesses.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Nolé F
    Ann Oncol; 2015 Jul; 26(7):1511-2. PubMed ID: 25846552
    [No Abstract]   [Full Text] [Related]  

  • 30. Second-line treatment for renal cell cancer.
    Di Lorenzo G; De Placido S; Buonerba C
    Br J Cancer; 2012 Feb; 106(4):617-8. PubMed ID: 22333706
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Systemic therapy of metastatic renal cell carcinoma].
    Maute L; Bergmann L
    Dtsch Med Wochenschr; 2016 Apr; 141(7):466-9. PubMed ID: 27031198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
    Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess G; Borker R; Fonseca E
    Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
    Kourie HR; Bakouny Z; Eid R; Haddad FG; Kattan J
    Future Oncol; 2018 Apr; 14(9):829-835. PubMed ID: 29589470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
    Atala A
    J Urol; 2013 Sep; 190(3):1132. PubMed ID: 23931237
    [No Abstract]   [Full Text] [Related]  

  • 39. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
    Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
    Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.